Myles Minter

Stock Analyst at William Blair

(2.62)
# 2,356
Out of 5,182 analysts
25
Total ratings
57.89%
Success rate
15.12%
Average return

Stocks Rated by Myles Minter

Korro Bio
Feb 17, 2026
Upgrades: Outperform
Price Target: n/a
Current: $12.84
Upside: -
Neumora Therapeutics
Feb 17, 2026
Upgrades: Outperform
Price Target: n/a
Current: $2.22
Upside: -
Biohaven
Nov 5, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $9.59
Upside: -
Alector
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.35
Upside: -
Dianthus Therapeutics
Jul 2, 2025
Initiates: Outperform
Price Target: n/a
Current: $87.16
Upside: -
Immunic
Mar 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $9.98
Upside: -
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.44
Upside: -
argenx SE
Nov 1, 2024
Upgrades: Outperform
Price Target: n/a
Current: $783.74
Upside: -
Arcturus Therapeutics Holdings
Jul 24, 2023
Initiates: Outperform
Price Target: $71
Current: $8.30
Upside: +755.42%
Moderna
Jul 24, 2023
Initiates: Market Perform
Price Target: n/a
Current: $48.70
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $426.01
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $330.99
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $4.44
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $308.51
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $72.23
Upside: -
Initiates: Outperform
Price Target: $116
Current: $128.04
Upside: -9.40%